

Lipid Transport and Blood Lipid Levels

Dave Bridges

June 9, 2026

Lipid transport is essential to both the efficient storage, and effective use of lipids. Due to their semi-or total insoluble nature, triglycerides, cholesterol and fatty acids present some specific technical problems in terms of transportation. These processes rely on both carrier proteins such as albumin as well as lipoprotein particles to safely move lipids from one tissue to another. Inefficient co-ordination of lipid transport can lead to elevated blood lipids, which are highly associated with cardiovascular disease, a major cause of death in modern society. For more details about lipid transport refer to Chapter 18 in Lippincott's Illustrated Reviews: Biochemistry, available in reserve¹.

¹ Denise Ferrier. *Lippincott Illustrated Reviews: Biochemistry*. LWW, 1496344499, 2017. ISBN 1-4963-4449-9

Contents

<i>Learning Objectives</i>	2
<i>Key Concepts and Vocabulary</i>	2
<i>Triglyceride and Fatty Acid Transport Mechanisms</i>	2
<i>Lipolysis and Fatty Acid Transport</i>	3
<i>Lipoprotein Particles in the Body</i>	3
<i>The Role of Chylomicrons and VLDL</i>	3
<i>The Role and Regulation of Lipoprotein Lipase</i>	4
<i>Reverse Cholesterol Transport</i>	5
<i>Synthesis and Role of HDL</i>	5
<i>LDL-mediated Transport to the Liver</i>	6
<i>Cholesterol Export to Bile</i>	6
<i>Blood Lipids and Cardiovascular Risk</i>	6
<i>Reflection Questions</i>	7
<i>Lipid Unit Integration Questions</i>	8

Learning Objectives

- Explain why lipoproteins are necessary for triglyceride and cholesterol transport.
- Describe the main carriers of cholesterol and triglyceride throughout the body, including how their apolipoproteins affect their endocytosis or catabolism.
- Apply your knowledge of cholesterol transport to explain why someone may have changes in HDL and LDL levels.
- Understand the etiology of high cholesterol and its potential role in atherosclerosis.
- Apply your understanding of cholesterol absorption, synthesis and transport to evaluate the relationships between dietary cholesterol and triglycerides and cardiovascular risk.
- Explain the role of lipoprotein lipase in lipid transport, including how it is regulated.

Key Concepts and Vocabulary

- Lipoprotein particles including:
 - Chylomicrons
 - Very Low Density Lipoproteins (VLDL)
 - Low Density Lipoproteins (LDL)
 - High Density Lipoproteins (HDL)
- Apolipoproteins, especially ApoB48, ApoB100 and ApoCII
- Lipoprotein Lipase and its regulation
- Reverse Cholesterol Transport
- Trans-Intestinal Cholesterol Export (TICE)
- Fatty Acid Transport and Albumin

Triglyceride and Fatty Acid Transport Mechanisms

Transportation of lipids presents some logistical problems. Since they are inherently insoluble, lipids need to be either solubilized prior to transport to other tissues via the blood stream. This is accomplished in two ways. One is the packaging of triglycerides and cholesterol esters into lipoprotein particles, such as the chylomicrons discussed

earlier in this unit. The second mechanism is to break triglycerides down to fatty acids, where they can bind to solubilizing proteins called albumin within the blood.

Lipolysis and Fatty Acid Transport

As we described in the unit about lipid oxidation, the majority of our triglyceride stores are in adipose tissue. The release of free fatty acids and glycerol from adipose tissue is a highly regulated process, activated by adrenaline and inhibited by insulin (for more details see Zechner et al. [2012] for a review). The transport of free fatty acids after release from adipose tissue is mediated by albumin, a very abundant protein produced by the liver. Due to their semi-solubility, fatty acids also require transport systems and fatty acid binding proteins (abbreviated as FABP) to move through membranes and through the cytoplasm.

Lipoprotein Particles in the Body

In terms of moving triglycerides and cholesterol esters, we have a variety of lipoprotein particles that play different roles in the body. These are summarized in Table 1. There are three main transport routes. The first is from the enterocyte to the periphery, mediated by chylomicrons. The second is from the liver to the periphery, mediated by VLDL. The third is from the periphery back to the liver, mediated by HDL and LDL. We will discuss each of these in the next few sections.

The goal of these lipoprotein particles is to move lipids from the source² to peripheral tissues which might be better equipped to utilize or store these lipids. As summarized in Table 2, these particles are characterized by distinct lipoproteins.

The Role of Chylomicrons and VLDL

Both chylomicrons and VLDL function to move lipids to peripheral tissues, either from the gastrointestinal tract or the liver, respectively. These particles transport primarily *neutral lipids* rather than free fatty acids. Their assembly is dependent on the production of the apolipoproteins and the presence of phospholipids, especially phosphatidylcholine that is important for their synthesis. If choline levels are limited, either due to less active variants in *PEMT* or reduced choline dietary intake, the liver will be less able to assemble VLDL. This can result in increased hepatic steatosis, potentially leading to metabolic dysfunction associated fatty liver disease.

Table 1: Summary of lipoprotein particles.

Particle	Source	Destination
Chylomicron	Enterocyte	Adipose, Muscle, Liver
VLDL	Liver	Adipose, Muscle
IDL	VLDL	Liver or LDL
HDL	Endothelial	LDL
LDL	IDL/HDL	Liver

² The source of chylomicrons transporting dietary lipids is the enterocyte, or the source of VLD is the liver; the function of lipoproteins is to transport the lipids from both these sources, enterocyte and liver

Table 2: Apolipoprotein summary. Some key things to remember, ApoB48 is specifically made in the enterocyte. ApoB100 and ApoE are the ligands for the LDL Receptor allowing for LDL uptake in tissues expressing the LDL receptor (mainly the liver). ApoCII is a coenzyme for LPL thus activating it and allowing for lipid extraction to peripheral tissues.

Particle	ApoA	ApoB	ApoC	ApoE
Chylomicron	AV	B48	CII/CIII	E
VLDL	AV	B100	CI/CII	E
IDL		B100		E
HDL	AI/AII			E
LDL		B100		

The Role and Regulation of Lipoprotein Lipase

Both VLDL and chylomicrons are targeted to peripheral tissues. This specificity is mediated by Apolipoprotein CII. This protein acts as an activator of a triglyceride lipase known as *Lipoprotein Lipase* or LPL. This lipase resides on the lumen of blood vessels, adjacent to muscle and adipose tissues. Once activated by ApoCII binding, LPL breaks down the triglycerides in the particle and releases its free fatty acid content. These free fatty acids enter the cell where they can be stored (if they enter into the adipocytes), or are used as fuel (if they enter into the muscle cells). The levels of LPL are inversely regulated in adipose and muscle tissue. For example, insulin promotes LPL transcription in adipose tissue³ but decreases LPL transcription in muscle [Spooner et al., 1979]. The inverse is true during fasting, where the muscle LPL transcription is increased while that of the adipose tissue is reduced thus promoting muscle uptake of fat to be used as energy, while limiting adipose tissue ability to store this fat in times of energy need (fasting).

LPL IS INACTIVATED BY DIETS HIGH IN SATURATED FATS. This means that when saturated fat levels are increased, LPL activity is reduced. You can imagine how this is no beneficial to the body, as the lipids in the blood cannot be taken up into the muscles or adipose tissue, therefore remaining in the blood and circulation. This is a negative feedback mechanism wherein intracellular lipids can signal to the LPL on the extracellular surface to prevent additional fat uptake (see Figure 1). The molecular underpinnings of this phenomena have recently been determined and involve the transcriptional activation of a protein called ANGPTL4⁴. ANGPTL4 is induced when excess fatty acid levels in the cell activate the transcription factor PPAR α . ANGPTL4 is then secreted where it binds to and inhibits the activity of LPL (more details about this can be found in the recent review by Dijk and Kersten [2014]). Mutations in either the *LPL* or *ANGPTL4* genes result in either impaired, or enhanced blood lipid clearance, respectively and as a result either lead to an increased or decreased risk of cardiovascular disease [Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators et al., 2016].

DEPLETED VLDL ARE KNOWN AS IDL, WHEREAS DEPLETED CHYLOMICRONS ARE KNOWN AS CHYLOMICRON REMNANTS. Once these lipoproteins have delivered their triglyceride content into cells, they are either known as chylomicron remnants or intermediate⁵ density lipoproteins (IDL). Due to the presence of ApoE on their surface, chylomicron remnants and IDL particles can be absorbed by the liver

³ To promote lipid storage. This is accomplished by both transcriptional and post-translational mechanisms, reviewed in Kersten [2014].

⁴ Unhelpfully, an abbreviation for Angiotensin-like 4.




Figure 1: Regulation of Lipoprotein Lipase (LPL) by ANGPTL4.

⁵ This indicates that this lipoprotein has intermediate density that falls in between VLDL and LDL's density

where the apolipoproteins and phospholipids can be reused.

APOE VARIANTS ARE ASSOCIATED WITH DISEASE RISK. ApoE is present on both chylomicrons and the VLDL that then form IDL/LDL. This gene is the major heritable risk factor for late onset Alzheimer's disease. There are four variants of the *APOE* gene numbered 1–4⁶. Of these isoforms, ApoE2 is thought to be protective of Alzheimer's disease and associated with lower levels of LDL-cholesterol⁷ while ApoE4 is a strong risk factor for late-onset Alzheimer's disease, and is associated with higher levels of LDL-cholesterol [Poirier et al., 1993, Corder et al., 1993].

⁶ These are variants of the same gene, not different genes

⁷ This appears to be specific to the *APOE* gene, as other genetic factors that have more pronounced effects on LDL-cholesterol do not have as strong an association with AD.

Reverse Cholesterol Transport

Cholesterol is primarily disposed of via bile salt generation and excretion, a process that starts in the liver. Therefore cholesterol, which is made throughout the body, is primarily trafficked to the liver, a process known as *Reverse Cholesterol Transport*. This process is mediated by both HDL and LDL particles. To separate blood lipids between reverse and forward transport processes, sometimes the ratio between ApoB and ApoAI is determined⁸. An alternate cholesterol disposal pathway is through the intestine, a process known as transintestinal cholesterol excretion (TICE). In this pathway, cholesterol is transported by either HDL or LDL directly to the intestine for efflux. Estimates vary, but we think that somewhere between 20 and 40% of cholesterol excretion is through TICE, with the remainder being through biliary transport [Temel and Brown, 2015].

⁸ Consider based on the data in Table 2 what this ratio is actually measuring. As a hint, a high ApoB100/ApoA1 ratio is indicative of elevated cardiovascular risk.

Synthesis and Role of HDL

High density lipoprotein particles start off as nascent particles containing ApoAI, ApoAII and very little cholesterol. As they pass through the circulation, they bind cholesterol from the plasma membrane of tissues and become enriched with cholesterol. Since most tissues make but cannot dispose of cholesterol, HDL is important for scavenging excess cholesterol from our cells. The HDL particles may be endocytosed in the liver where cholesterol can be disposed, but most often they transfer their cholesterol to LDL particles using an enzyme known as cholesterylester transfer protein⁹. This ensures that triglycerides are packaged in the LPL-accessible particles for peripheral transport to be used by peripheral tissues, while excess cholesterol is delivered back to the liver or intestine for excretion. Inhibition of CETP results in an increase in the amount of HDL cholesterol in the blood and thus CEPT inhibition was a heavily invested pharma-

⁹ Abbreviated as CETP

cological area, but these drugs have shown limited cardiovascular benefits. The current thinking in this area is that high HDL cholesterol is a marker of lowered cardiovascular risk but does not cause lowered cardiovascular risk by itself.

LDL-mediated Transport to the Liver

Low density lipoproteins are generated when IDL derived from VLDL remains in the circulation, or when cholesterol is passed from an HDL to an IDL particle. These particles tend to be cholesterol rich, since the triglycerides have been already taken up due to the actions of LPL at peripheral tissues. These particles would normally be endocytosed by the liver where LDL receptors are found. LDLR levels are under control of the SREBP2. Recall that when intrahepatic cholesterol levels are high, SREBP2 is inactive, and thus LDLR would not be produced. This means that when the liver has sufficient cholesterol, LDL particles remain in the circulation¹⁰. LDL cholesterol levels are correlated with coronary events. If one wants to understand the levels of LDL cholesterol in a person there are two measures to consider. By looking at how much cholesterol is in the LDL fraction (LDL-C, should be less than 100 mg/dL) or how many LDL particles are present in the blood. Since each LDL contains one, and only one ApoB100 particle, and since LDL particles vastly outnumber VLDL particles, then if you determine the concentration of ApoB100 in blood, then that is a measure of LDL particle number. Recent studies have suggested that it is this particle number, more so than the amount of cholesterol in the LDL fraction, that is more predictive of cardiovascular events, though generally both the cholesterol content in LDL and the LDL particle number increase for most people simultaneously [Cromwell et al., 2007, Mora et al., 2007].

¹⁰ As a thought exercise, consider what would happen if you had a *LDLR* mutation, how would that affect cholesterol retrieval? How do you think it would affect cholesterol synthesis? This is the case for individuals with a disease known as familial hypercholesterolemia.

Cholesterol Export to Bile

Within the liver, bile salt synthesis is controlled by the activity of 7- α -hydroxylase¹¹ and exported to the gallbladder for release into the digestive system. Separate from the SREBP2-dependent cholesterol regulatory system, the production of bile salts is sensed by the FXR sensing system¹².

¹¹ We discussed this in the lipid digestion lecture

¹² FXR is a bile acid sensor expressed in entero-hepatic tissues.

Blood Lipids and Cardiovascular Risk

If lipid transport systems (of VLDL and LDL) have exceeded their ability to store lipids, then VLDL and LDL lipids remain in the blood. Akin to the hyperglycemia associated with impaired glucose disposal, and excessive glucose production, hyperlipidemia is associated

with cardiovascular disease due to impaired lipid disposal. Since triglycerides can be metabolized into energy by most tissues, but cholesterol cannot, hypercholesterolemia in particular has been long associated with cardiovascular risk [Keys et al., 1963].

Since cholesterol may exist in several lipoprotein particles, a more prognostic indicator of cardiovascular risk is the amount of cholesterol in HDL particles relative to the amount of cholesterol in LDL particles, with the latter being more pathogenic¹³. Several mechanisms for LDL's specific association with cardiovascular risk have been proposed, but one possibility is that excess LDL is absorbed in blood vessel walls, promoting both atherosclerosis¹⁴ and increasing the risk of thrombosis¹⁵.

FROM A DIETARY STANDPOINT, data from several US-based cohort studies demonstrated that diets lower in saturated fat intake are associated with both lower total and LDL cholesterol, and with reductions in cardiovascular disease [Anderson et al., 1987, Wang et al., 2016]. This has recently been challenged by a large-multi country study¹⁶ which indicated that increased carbohydrate intake plays a key role, maybe more so than saturated fats with respect to cardiovascular disease [Mente et al., 2017]. For this large multi-ethnic study, there is some debate about whether regional dietary differences are fully accounted for, or if this is more reflective of diet-disease risk in a more diverse dataset.

Reflection Questions

1. A patient carries a loss-of-function mutation in ANGPTL4. Predict the effects on: (a) LPL activity after a high-fat meal, (b) circulating triglyceride levels, and (c) the distribution of dietary fatty acids between adipose and muscle. Then explain why population studies have associated ANGPTL4 loss-of-function variants with reduced cardiovascular disease risk.
2. Patient A has elevated LDL-C but a normal ApoB100 concentration. Patient B has normal LDL-C but elevated ApoB100. Using your knowledge of VLDL-to-LDL progression and what each measurement represents, evaluate which patient is at higher cardiovascular risk and why, and describe what metabolic or genetic conditions could produce each pattern.
3. A patient carries the ApoE4 allele and has elevated LDL cholesterol. They ask whether reducing dietary cholesterol is the best strategy to lower their LDL. Apply your knowledge of SREBP2 regulation, LDLR expression, and the relationship between dietary

¹³ HDL cholesterol levels may indicate a surplus of cholesterol transport particles, whereas LDL cholesterol likely indicates a surplus of cholesterol that cannot be absorbed by the liver.

¹⁴ The lipid-based coating of arteries, causing arteries to become narrower and reducing their vascular flexibility.

¹⁵ The release of a blood clot, often by lysis and release of an atherosclerotic plaque. This blood clot could travel to the brain or heart where a stroke or heart attack may occur.

¹⁶ This is known as the PURE study, which evaluated over 135 000 participants in 18 countries.

and endogenous cholesterol to advise this patient, and explain what interventions targeting different steps in the system might be more effective.

Lipid Unit Integration Questions

1. A person eats a meal containing a grilled salmon fillet (rich in ω -3 PUFA and protein), roasted vegetables (fiber and fat-soluble vitamins), and olive oil dressing (MUFA). Trace the complete fate of the dietary lipids from digestion through absorption, chylomicron assembly, peripheral delivery, and eventual storage or oxidation. Your answer should address bile salt function, LPL regulation, the differential handling of PUFA vs. MUFA, and how the fiber in the meal might modify cholesterol absorption.
2. A patient with type 2 diabetes and MASLD presents with hypertriglyceridemia, low HDL, and elevated LDL particle number despite a normal LDL-C. Using your knowledge of the entire lipid unit, explain how insulin resistance simultaneously drives: excess VLDL secretion from the liver (via unrestrained de novo lipogenesis and impaired insulin suppression), impaired LPL activity in muscle, unrestrained lipolysis in adipose, and how excess hepatic Acetyl-CoA from both fatty acid oxidation and de novo synthesis contributes to the overall picture.
3. An endurance athlete on a very low carbohydrate ketogenic diet completes a four-hour training ride. Trace the metabolic events from adipose lipolysis through fatty acid transport (albumin, LPL, CPTI), β -oxidation, hepatic ketogenesis, and peripheral ketolysis in muscle. Include the role of malonyl-CoA in preventing futile cycling, explain why the brain can shift to using ketone bodies, and calculate (approximately) the energetic cost of using ketone bodies rather than direct glucose oxidation.
4. A patient with familial hypercholesterolemia (loss-of-function LDLR mutation) is started on a statin plus ezetimibe combination. Using your knowledge of cholesterol synthesis (HMGCR, SREBP2), intestinal absorption (NPC1L1, SREBP2 in enterocytes), bile acid cycling (enterohepatic circulation, fiber), and LDL particle clearance (LDLR), evaluate the mechanism of each drug, predict their combined effect on LDL-C, and explain why combination therapy is more effective than either drug alone.
5. Four dietary or lifestyle interventions have been proposed to reduce cardiovascular disease risk: (1) reducing dietary cholesterol intake, (2) replacing saturated fatty acids with monounsaturated

fatty acids, (3) increasing soluble fiber intake, and (4) improving insulin sensitivity through exercise or weight loss. Using your knowledge of cholesterol absorption (NPC1L1, SREBP2), synthesis (HMGCR), lipoprotein metabolism, and the role of insulin in lipid homeostasis, compare and contrast the mechanistic basis and expected effectiveness of each intervention on LDL-C and cardiovascular risk. Which intervention(s) would you prioritize for a patient with type 2 diabetes and elevated LDL particle number, and why?

- Chronic alcohol consumption is associated with hypertriglyceridemia, elevated LDL-C, and increased cardiovascular disease risk. Using your knowledge of alcohol metabolism (ADH vs. CYP2E1 pathways), hepatic NADH generation, effects on TCA cycle activity, de novo lipogenesis, VLDL secretion, and oxidative stress on LDL particles, trace the mechanistic pathway from alcohol consumption to cardiovascular risk. Your answer should distinguish between moderate and heavy drinking, and explain why the shift from ADH to CYP2E1 in heavy drinkers worsens the lipid phenotype.

References

- Keaven M. Anderson, William P. Castelli, and Daniel Levy. Follow-up From the Framingham Study. *Jama*, (257):2176–2180, 1987.
- E. Corder, A. Saunders, W. Strittmatter, D. Schmechel, P. Gaskell, G. Small, A. Roses, J. Haines, and M. Pericak-Vance. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*, 261(5123):921–923, 1993. ISSN 0036-8075. DOI: 10.1126/science.8346443.
- William C. Cromwell, James D. Otvos, Michelle J. Keyes, Michael J. Pencina, Lisa Sullivan, Ramachandran S. Vasan, Peter W.F. Wilson, Ralph B. D'Agostino, and Ralph B. D'Agostino. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - Implications for LDL management. *Journal of Clinical Lipidology*, 1(6):583–592, December 2007. ISSN 19332874. DOI: 10.1016/j.jacl.2007.10.001.
- Wieneke Dijk and Sander Kersten. Regulation of lipoprotein lipase by Angptl4. *Trends in Endocrinology & Metabolism*, 25(3):146–155, 2014. ISSN 10432760. DOI: 10.1016/j.tem.2013.12.005.
- Denise Ferrier. *Lippincott Illustrated Reviews: Biochemistry*. LWW, 1496344499, 2017. ISBN 1-4963-4449-9.

Sander Kersten. Physiological regulation of lipoprotein lipase.

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1841(7):919–933, 2014. ISSN 13881981. DOI: 10.1016/j.bbaliip.2014.03.013.

Ancel Keys, Henry Taylor, Henry Blackburn, Joseph Brozek, Joseph Anderson, and Ernst Simonson. Coronary Heart Disease among Minnesota Business and Professional Men Followed Fifteen Years. *Circulation*, 28(3):381–395, 1963. ISSN 0009-7322. DOI: 10.1161/01.CIR.28.3.381.

Andrew Mente, Mahshid Dehghan, Sumathy Rangarajan, Matthew McQueen, Gilles Dagenais, Andreas Wielgosz, Scott Lear, Wei Li, Hui Chen, Sun Yi, Yang Wang, Rafael Diaz, Alvaro Avezum, Patricio Lopez-Jaramillo, Pamela Seron, Rajesh Kumar, Rajeev Gupta, Viswanathan Mohan, Sumathi Swaminathan, Raman Kutty, Katarzyna Zatonska, Romaina Iqbal, Rita Yusuf, Noushin Mohammadifard, Rasha Khatib, Nafiza Mat NM Nasir, Noorhassim Ismail, Aytekin Oguz, Annika Rosengren, AM M. Afzal-hussein M. Yusufali, Edelweiss Wentzel-Viljoen, Thandi Puoane, Jephath Chifamba, Koon K. Teo, Sonia S. Anand, Salim Yusuf, C. K. Chow, M. O'Donnell, D. Leong, A. Smyth, P. Joseph, A. Merchant, Shofiqul Islam, M. Zhang, W. Hu, C. Ramasundarahettige, G. Wong, Shrikant I. Bangdiwala, L. Dyal, A. Casanova, G. Lewis, A. Aliberti, A. Arshad, A. Reyes, A. Zaki, B. Lewis, B. Zhang, D. Agapay, D. Hari, E. Milazzo, E. Ramezani, F. Hussain, F. Shifaly, G. McAlpine, I. Kay, J. Lindeman, J. Rimac, J. Swallow, L. Heldman, M(a) M(o) Mushtaha, M. Trottier, M. Riggi, N. Aoucheva, N. Kandy, P. Mackie, R. Solano, S. Chin, S. Ramacham, S. Shahrook, S. Trottier, T. Tongana, W. ElSheikh, Y. Iyengar, Kevin D. Hall, J. Keys, X. Wang, J. Keneth, A. Devanath, A. Orlandini, B. Linetsky, S. Toscanelli, G. Casaccia, JM Maini Cuneo, O. Rahman, AK K. Azad, K. A. KA A. Rabbani, H. M. HM Cherry, A. Mannan, I. Hassan, A. T. AT Talukdar, R. B. RB Tooheen, M. U. MU Khan, M. Sintaha, T. Choudhury, R. Haque, S. Parvin, GB B. Oliveira, C. S. CS Marcilio, A. C. AC C. Mattos, J. Dejesus, P. Poirier, G. Turbide, D. Auger, A. LeBlanc Blanc De Bluts, M. C. MC Proulx, M. Cayer, N. Bonneville, D. Gasevic, E. Corber, V. de Jong, I. Vukmirovich, G. Fodor, A. Pipe, A. Shane, F. Lanas, S. Martinez, A. Valdebenito, M. Oliveros, Li Wei, Liu Lisheng, Chen Chunming, Wang Xingyu, Zhao Wenhua, Zhang Hongye, Jia Xuan, Hu Bo, Bo Jian, Zhao Xi-uwen, Chang Xiaohong, Chen Tao, Chen Hui, Deng Qing, Cheng Xiaoru, He Xinye, Li Jian, Li Juan, Liu Xu, Ren Bing, Wang Wei, Wang Yang, Yang Jun, Zhai Yi, Zhu Manlu, Lu Fanghong, Wu Jianfang, Li Yindong, Hou Yan, Zhang Liangqing, Guo Baoxia, Liao

Xiaoyang, Zhang Shiyang, Bian Rongwen, Tian Xiuzhen, Li Dong, Chen Di, Wu Jianguo, Xiao Yize, Liu Tianlu, Zhang Peng, Dong Changlin, Li Ning, Ma Xiaolan, Yang Yuqing, Lei Rensheng, Fu Minfan, He Jing, Liu Yu, Xing Xiaojie, Zhou Qiang, PA Camacho Lopez, R. Garcia, LJA J.A. Jurado, D. Gómez-Arbeláez, J. F. JF Arguello, R. Dueñas, S. Silva, L. P. LP Pradilla, F. Ramirez, D. I. DI Molina, C. Cure-Cure, M. Perez, E. Hernandez, E. Arcos, S. Fernandez, C. Narvaez, J. Paez, A. Sotomayor, H. Garcia, G. Sanchez, T. David, A. Rico, P. Mony, M. Vaz, A. V. Bharathi, K. Shankar AV Kurpad, K. G. KG Jayachitra, N. Kumar, HAL A.L. Hospital, M. Deepa, K. Parthiban, M. Anitha, S. Hemavathy, T. Rahulashankiruthiyayan, D. Anitha, K. Sridevi, RB B. Panwar, I. Mohan, P. Rastogi, S. Rastogi, R. Bhargava, J. S. Thakur, B. Patro, PVM V.M. Lakshmi, R. Mahajan, P. Chaudary, V. Raman Kutty, K. Vijayakumar, K. Ajayan, G. Rajasree, A. R. Renjini, A. Deepu, B. Sandhya, S. Asha, H. S. Soumya, R. Kelishadi, A. Bahonar, H. Heidari, K. Yusoff, TST S.T. Ismail, K. K. KK Ng, A. Devi, M. M. MM Yasin, M. Miskan, EA A. Rahman, MKM K.M. Arsad, F. Ariffin, S. A. SA A. Razak, F. A. FA Majid, N. A. NA A. Bakar, M. Y. Yacob, N. Zainon, R. Salleh, MKA K.A. Ramli, N. A. NA A. Halim, SR R. Norlizan, N. M. NM M. Ghazali, M. N. MN Arshad, R. Razali, S. Ali, H. R. HR Othman, CWJCW W.J.C.W. Hafar, A. Pit, N. Danuri, F. Basir, SNA N.A. Zahari, H. Abdullah, M. A. MA Arippin, N. A. NA Zakaria, I. Noorhassim, MJ J. Hasni, MT T. Azmi, M. I. MI Zaleha, K. Y. KY Hazdi, A. R. AR R. Rizam, W. Sazman, A. Azman, U. Khammash, A. Khatib, R. Giacaman, A. Afridi, R. Khawaja, A. Raza, K. Kazmi, A. Dans, H. U. Co, J. T. Sanchez, L. Pudol, C. Zamora-Pudol, L. A.M. Palileo-Villanueva, M. R. Aquino, C. Abaquin, S. L. Pudol, M. L. Cabral, W. Zatonski, Andrzej Szuba, R. Ilow, M. Ferus, B. Regulska-Ilow, D. Rózanska, M. Wolyniec, K. F. AlHabib, A. Hersi, T. Kashour, H. Alfaleh, M. Alshamiri, H. B. Altaradi, O. Alnobani, A. Bafart, N. Alkamel, M. Ali, M. Abdulrahman, R. Nouri, A. Kruger, H. H. Voster, A. E. Schutte, F. C. FC C. Eloff, H. de Ridder, H. Moss, J. Potgieter, A. A. AA Roux, M. Watson, G. de Wet, A. Olckers, J. C. JC Jerling, M. Pieters, T. Hoekstra, E. Igumbor, Lungiswa Tsolekile, D. Sanders, P. Naidoo, N. Steyn, N. Peer, B. Mayosi, B. Rayner, V. Lambert, N. Levitt, T. Kolbe-Alexander, L. Ntyintyane, G. Hughes, R. Swart, J. Fourie, M. Muzigaba, S. Xapa, N. Gobile, K. Ndayi, B. Jwili, K. Ndibaza, B. Egbujie, Kristina Bengtsson Boström, A. Gustavsson, M. Andreasson, M. Snällman, L. Wirdemann, K. Yeates, J. Sleeth, K. Kilonzo, N. Imeryuz, Y. Altuntas, S. Gulec, A. Temizhan, K. Karsidag, KBT B.T. Calik, AAK A.K. Akalin, O. T. OT T. Caklili, M. V. MV Keskin-

ler, A. N. AN Erbakan, W. Almahmeed, H. Swidan, E. A. EA Darwish, ARA R.A. Hashemi, N. Al-Khaja, J. M. JM Muscat-Baron, S. H. SH Ahmed, TM M. Mamdouh, W. M. WM Darwish, M. H.S. Abdelmotagali, SA Omer Awed, G. A. GA A. Movahedi, H. Al Shaibani, RIM I.M. Gharabou, D. F. DF Youssef, AZS Z.S. Nawati, ZAR Abu Salah, RFE F.E. Abdalla, S. M. SM Al Shuwaihi, M. A. MA Al Omairi, O. D. OD D. Cadigal, R.S. S. Alejandrino, L. Gwaunza, G. Terera, C. Mahachi, P. Murambiwa, T. Machiweni, R. Mapanga, Xiaohe Zhang, Leela Itty Amma, Xiaoyun Liu, Nan Gao, Anis Safura Ramli, Yi Sun, Afzal Hussein Yusufali, Alkamel, M. A. Kruger, and K. Bengtsson Boström. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: A cross-sectional analysis from the PURE study. *The Lancet Diabetes & Endocrinology*, 5(10):774–787, August 2017. ISSN 22138595. DOI: 10.1016/S2213-8587(17)30283-8.

Samia Mora, Moyses Szklo, James D. Otvos, Philip Greenland, Bruce M. Psaty, David C. Goff, Daniel H. O’Leary, Mohammed F. Saad, Michael Y. Tsai, and A. Richey Sharrett. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*, 192(1):211–217, 2007. ISSN 00219150. DOI: 10.1016/j.atherosclerosis.2006.05.007.

Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Nathan O Stitzziel, Kathleen E. Stirrups, Nicholas G. D. Masca, Jeanette Erdmann, Paola G Ferrario, Inke R König, Peter E Weeke, Thomas R Webb, Paul L Auer, Ursula M Schick, Yingchang Lu, He Zhang, Marie-Pierre Dube, Anuj Goel, Martin Farrall, Gina M Peloso, Hong-Hee Won, Ron Do, Erik van Iperen, Stavroula Kanoni, Jochen Kruppa, Anubha Mahajan, Robert A Scott, Christina Willenborg, Peter S Braund, Julian C van Capelleveen, Alex S F Doney, Louise A Donnelly, Rosanna Asselta, Piera A Merlini, Stefano Duga, Nicola Marziliano, Josh C Denny, Christian M Shaffer, Nour Eddine El-Mokhtari, Andre Franke, Omri Gottesman, Stefanie Heilmann, Christian Hengstenberg, Per Hoffman, Oddgeir L Holmen, Kristian Hveem, Jan-Håkan Jansson, Karl-Heinz Jöckel, Thorsten Kessler, Jennifer Kriebel, Karl L Laugwitz, Eirini Marouli, Nicola Martinelli, Mark I McCarthy, Natalie R Van Zuydam, Christa Meisinger, Tõnu Esko, Evelin Mihailov, Stefan A Escher, Maris Alver, Susanne Moebus, Andrew D Morris, Martina Müller-Nurasyid, Majid Nikpay, Oliviero Olivieri, Louis-Philippe Lemieux Perreault, Alaa AlQarawi, Neil R Robertson, Karen O Akinsanya, Dermot F Reilly, Thomas F. Vogt, Wu Yin, Folkert W Asselbergs, Charles Kooperberg, Rebecca D Jackson,

- Eli A. Stahl, Konstantin Strauch, Tibor V Varga, Melanie Waldenberger, Lingyao Zeng, Aldi T. Kraja, Chunyu Liu, George B Ehret, Christopher Newton-Cheh, Daniel I Chasman, Rajiv Chowdhury, Marco Ferrario, Ian Ford, J Wouter Jukema, Frank Kee, Kari Kuulasmaa, Børge G Nordestgaard, Markus Perola, Danish Saleheen, Naveed Sattar, Praveen Surendran, David-Alexandre Tregouet, Robin Young, Joanna M M Howson, Adam S Butterworth, John Danesh, Diego Ardissino, Erwin P. Bottinger, Raimund Erbel, Paul W. Franks, Domenico Girelli, Alistair S. Hall, G Kees Hovingh, Adnan Kastrati, Wolfgang Lieb, Thomas Meitinger, William E. Kraus, Svati H Shah, Ruth McPherson, Marju Orho-Melander, Olle Melander, Andres Metspalu, Colin N A Palmer, Annette Peters, Daniel Rader, Muredach P Reilly, Ruth J F Loos, Alex P Reiner, Dan M Roden, Jean-Claude Tardif, John R Thompson, Nicholas J Wareham, Hugh Watkins, Cristen J. Willer, Sekar Kathiresan, Panos Deloukas, Nilesh J Samani, and Heribert Schunkert. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. *The New England journal of medicine*, 374(12):1134–44, March 2016. ISSN 1533-4406. DOI: 10.1056/NEJMoa1507652.
- J. Poirier, P. Bertrand, J. Poirier, S. Kogan, S. Gauthier, J. Poirier, S. Gauthier, J. Davignon, D. Bouthillier, and J. Davignon. Apolipoprotein E polymorphism and Alzheimer's disease. *The Lancet*, 342(8873):697–699, 1993. ISSN 01406736. DOI: 10.1016/0140-6736(93)91705-Q.
- P M Spooner, S S Chernick, M M Garrison, and R O Scow. Insulin regulation of lipoprotein lipase activity and release in 3T3-L1 adipocytes. Separation and dependence of hormonal effects on hexose metabolism and synthesis of RNA and protein. *The Journal of biological chemistry*, 254(20):10021–9, October 1979. ISSN 0021-9258.
- Ryan E. Temel and J. Mark Brown. A new model of reverse cholesterol transport: EnTICEing strategies to stimulate intestinal cholesterol excretion. *Trends in Pharmacological Sciences*, 36(7):440–451, 2015. ISSN 18733735. DOI: 10.1016/j.tips.2015.04.002.
- Dong D. Wang, Yanping Li, Stephanie E. Chiuve, Meir J. Stampfer, JoAnn Ann E. Manson, Eric B. Rimm, Walter C. Willett, and Frank B. Hu. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. *JAMA internal medicine*, 176(8):1134–45, 2016. ISSN 2168-6114. DOI: 10.1001/jamainternmed.2016.2417.
- Rudolf Zechner, Robert Zimmermann, Thomas O. O. Eichmann, Sepp D. D. Kohlwein, Guenter Haemmerle, Achim Lass, and Frank

Madeo. FAT SIGNALS - Lipases and lipolysis in lipid metabolism and signaling. *Cell Metabolism*, 15(3):279–291, March 2012. ISSN 15504131. DOI: 10.1016/j.cmet.2011.12.018.